NCT07913256Not yet recruiting
The Impact of Rheumatoid Arthritis Treatments on the Modulation of Extracellular Vesicles and Other Biomarkers Involved in the Development of Lung Cancer
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
Patients with rheumatoid arthritis (RA) have an increased risk of lung cancer, potentially influenced by targeted therapies such as JAK inhibitors and biologics. Extracellular vesicles (EVs) are key mediators of intercellular communication and may carry biomarkers involved in oncogenesis. This study aims to compare EV concentration and molecular content in RA patients treated with different targeted therapies. The objective is to identify treatment-related differences in EV profiles that may contribute to lung cancer development and improve risk stratification.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 136 (estimated)
- First submitted
- 28 Oct 2026
- Start date
- 1 Dec 2026
- Primary completion date
- 1 Dec 2031
- Lead sponsor
- University Hospital, Limoges
- Diseases
- Rheumatoid arthritis, Lung cancer
- NCT number
- NCT07913256
What you commit to
- Study type: Observational
- Planned participants: 136
- From 1 Dec 2026 to the primary completion date, 1 Dec 2031
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Pregnant or breastfeeding women
- Patients under a protective regime (guardianship, curatorship)
Who the study is looking for
- Patients receiving rheumatology care at Limoges University Hospital
- Aged 18 years or over
- Diagnosis of RA established in accordance with the 2010 ACR (American College of Rheumatology) / EULAR (European League Against Rheumatism) classification criteria
- Patients who have been treated with a JAK inhibitor, anti-TNF agent, abatacept or anti-IL-6 for at least 1 month
- Patients capable of expressing their refusal
- Patients with up-to-date health insurance cover
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.